---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-115482"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:12:54.723210+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Q1 Portfolio Receipts $839M (+17% YoY); raises FY2025 guidance

## Summary
- Royalty Receipts grew 12% to $788M; cystic fibrosis franchise, Trelegy, Xtandi drove growth.
- Raised FY2025 Portfolio Receipts guidance to $2,975M-$3,125M (prior $2,900M-$3,050M).
- Repurchased 23M shares for $723M under new $3B buyback program.
- Internalization of manager RP Management ($1.1B) vote May 12, closing expected Q2 2025.
- Biogen R&D funding for litifilimab (up to $250M); $50M upfront in Q1.

## SEC filing metadata
- accession: 0001193125-25-115482
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/0001193125-25-115482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/d938501d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-115482
- JSON: https://secwatch.observer/filing/0001193125-25-115482.json
- Plain text: https://secwatch.observer/filing/0001193125-25-115482.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.